Dr. Eldon is a Partner with NDA Partners and has worked with the company as an Expert Consultant since 2017. He has more than 40 years of experience in clinical pharmacology, pharmacokinetics/pharmacodynamics, and pharmacometric modeling and simulation in the pharmaceutical industry.
As Vice President of Clinical Pharmacology at Nektar Therapeutics and a member of Nektar’s corporate-level Research and Clinical Development Committees, Eldon was responsible for clinical and preclinical pharmacokinetics, ADME, pharmacometrics and systems biology in drug development and discovery. While at Nektar, he participated in the discovery, development and registration of Movantik and Exubera (rH insulin for inhalation); and the discovery and preclinical and clinical development of other Nektar proprietary products including Onzeald (etirinotecan pegol), oxycodegol (NKTR-181), and bempegaldesleukin (NKTR-214). Prior to Nektar, Eldon worked at Parke-Davis Pharmaceutical Research where he participated in the development and registration of a range of pharmaceutical drug products.